Last reviewed · How we verify
desogestrel/ethinyl estradiol
Desogestrel/ethinyl estradiol is a combined oral contraceptive that prevents pregnancy by suppressing ovulation through progestin and estrogen activity.
Desogestrel/ethinyl estradiol is a combined oral contraceptive that prevents pregnancy by suppressing ovulation through progestin and estrogen activity. Used for Contraception (prevention of pregnancy), Acne vulgaris (in some formulations).
At a glance
| Generic name | desogestrel/ethinyl estradiol |
|---|---|
| Sponsor | Teva Branded Pharmaceutical Products R&D, Inc. |
| Drug class | Combined oral contraceptive |
| Target | Progesterone receptor, estrogen receptor |
| Modality | Small molecule |
| Therapeutic area | Contraception / Gynecology |
| Phase | FDA-approved |
Mechanism of action
The progestin desogestrel inhibits the luteinizing hormone (LH) surge necessary for ovulation, while ethinyl estradiol suppresses follicle-stimulating hormone (FSH) to prevent follicle development. Together, these hormones also thicken cervical mucus and alter the endometrium to create a hostile environment for sperm and implantation.
Approved indications
- Contraception (prevention of pregnancy)
- Acne vulgaris (in some formulations)
Common side effects
- Nausea
- Headache
- Breast tenderness
- Breakthrough bleeding
- Mood changes
- Venous thromboembolism
Key clinical trials
- An Ethno-bridging Study of Pergoveris in Healthy Premenopausal Participants of Japanese or Caucasian Origin (PHASE1)
- BIOTRONIK Conduction System Pacing With the Solia Lead - Solia CSP S (NA)
- Combined Oral Contraceptive Pill and Resistance Starch (PHASE2)
- Studying Routine Patient Care With BIOTRONIK Devices That Allow a More Natural Heart Stimulation
- Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial (PHASE2)
- [Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer (PHASE1)
- Strengthening Hepatitis B Screening, Linkage to Care and Long-Term Monitoring in Phichit Province, Thailand: A Birth Bohort Approach (PHASE4)
- BIO|MASTER.CSP Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: